• The collaboration will evaluate combining the circVec generation 5 construct into POLARIS-101TM to address major unmet medical needs in genetic heart disease
• Solid Biosciences´ proprietary, next-generation AAV capsid, POLARIS-101, was engineered for enhanced cardiac and muscle tropism
• Circio´s latest circVec generation 5 has demonstrated up to 200-fold enhanced gene expression from AAV vectors in heart in vivo

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.